BRIEF—Early access to Bavencio combo in RCC

The UK’s Medicines and Healthcare Products Regulatory Agency has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for Bavencio (avelumab) in combination with Inlyta (axitinib) as a first-line treatment for advanced renal cell carcinoma (RCC).

This combination has not been approved in Europe for advanced RCC and is currently under review by the European Medicines Agency, so this status should give UK patients early access.

Bavencio is being jointly developed and commercialized by US pharma giant Pfizer and German life sciences company Merck KGaA.